GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » YoY EBITDA Growth

ALLK (Allakos) YoY EBITDA Growth : 60.45% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Allakos YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Allakos's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 60.45%.

Allakos's EBITDA per Share for the three months ended in Sep. 2024 was $-0.21.

Allakos YoY EBITDA Growth Historical Data

The historical data trend for Allakos's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos YoY EBITDA Growth Chart

Allakos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial 13.21 -57.89 -59.13 0.34 56.09

Allakos Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.08 -38.43 - 25.30 60.45

Allakos YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Allakos's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-2.188--4.983)/ | -4.983 |
=56.09 %

Allakos's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EBITDA Growth (Q: Sep. 2024 )
=(EBITDA per Share (Q: Sep. 2024 )-EBITDA per Share (Q: Sep. 2023 )) / | EBITDA per Share (Q: Sep. 2023 )) |
=(-0.212--0.536)/ | -0.536 |
=60.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allakos YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Allakos's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Allakos Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » YoY EBITDA Growth
Comparable Companies
AKBA STOK APLT VSTM ZVRA STRO GLUE IKNA OBIO QSI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
37Z:Germany
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Website
https://www.allakos.com
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Executives
Harlan Baird Radford officer: Chief Financial Officer C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Everett Rand Sutherland director 29 HARTWELL AVENUE, LEXINGTON MA 02421
Dolca Thomas director C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Daniel Janney director PO BOX 7414, JACKSON WY 83002
Amy L Ladd director INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086
Craig A. Paterson officer: Chief Medical Officer ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Margaret Nell Fitzgerald officer: General Counsel and Secretary ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Adam Tomasi officer: COO, CFO and Secretary ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Robert Alexander director, officer: President and CEO 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rasmussen Henrik S Md officer: Chief Medical Officer 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
John P Mckearn director, 10 percent owner 5820 NANCY DRIVE, SAN DIEGO CA 92121
Peter A Hudson 10 percent owner 701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067